Comparative Pharmacology
Head-to-head clinical analysis: LEUPROLIDE ACETATE versus TRELSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEUPROLIDE ACETATE versus TRELSTAR.
LEUPROLIDE ACETATE vs TRELSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Upon continuous administration, it suppresses pituitary gonadotropin secretion by downregulating GnRH receptors, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and consequently reducing sex steroid (testosterone and estrogen) production in the gonads.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced testicular and ovarian steroidogenesis.
Prostate cancer: 7.5 mg IM once monthly or 22.5 mg IM once every 3 months or 45 mg SC once every 6 months. Central precocious puberty: 50 mcg/kg/day SC or 7.5 mg IM once monthly. Endometriosis: 3.75 mg IM once monthly or 11.25 mg IM once every 3 months.
3.75 mg intramuscularly once every 4 weeks or 11.25 mg intramuscularly once every 12 weeks or 22.5 mg intramuscularly once every 24 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours following intravenous administration; after subcutaneous depot formulations, the effective half-life is extended due to slow release, with a terminal half-life of about 3-4 weeks for the 1-month depot.
Terminal elimination half-life approximately 3 weeks (21-28 days) after intramuscular injection; sustained release formulation results in prolonged exposure.
Renal: approximately 5% as unchanged drug; hepatic metabolism accounts for the majority of clearance, with metabolites excreted renally and fecally; biliary excretion is minimal.
Primarily hepatic metabolism; <5% excreted unchanged in urine; fecal elimination of metabolites accounts for approximately 20-30%.
Category D/X
Category C
GnRH Agonist
GnRH Agonist